title: Dementia in Parkinson's disease.
abstract: Dementia can occur in a substantial number of patients with Parkinson's disease with a point prevalence close to 30%. The cognitive profile is characterized by predominant deficits in executive, visuospatial functions, attention and memory. Behavioral symptoms are frequent such as apathy, visual hallucinations and delusions. The most prominent associated pathology is Lewy body-type and biochemical deficit is cholinergic. Placebo-controlled randomized trials with cholinesterase inhibitors demonstrated modest but significant benefits in cognition, behavioral symptoms and global functions.
authors.affiliation: Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey. Electronic address: hasmet@yahoo.com.
authors.forename: Hasmet A
authors.initials: HA
authors.lastname: Hanagasi
authors.affiliation: Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Tufekcioglu
authors.affiliation: Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul, Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Emre
mesh_terms: D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003704:Dementia / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000453:epidemiology
chemical_list: D002800:Cholinesterase Inhibitors
keywords: Cholinesterase inhibitors; Dementia; Dementia with Lewy Bodies; Parkinson's disease